Zentalis Pharmaceuticals (ZNTL) Institutional Ownership

During the previous two years, 101 institutional investors and hedge funds held shares of Zentalis Pharmaceuticals. The most heavily invested institutionals were Matrix Capital Management Company LP ($393.81M), Eventide Asset Management LLC ($175.13M), Vanguard Group Inc. ($69.32M), Decheng Capital Management III Cayman LLC ($59.23M), Price T Rowe Associates Inc. MD ($55.00M), Capital International Investors ($42.72M), and Avidity Partners Management LP ($42.13M).Learn more on ZNTL's institutional investors.

Of the 86 institutional investors that purchased Zentalis Pharmaceuticals stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Matrix Capital Management Company LP ($4.76M), Eventide Asset Management LLC ($4.68M), Decheng Capital LLC ($3.07M), Cormorant Asset Management LP ($1.10M), FMR LLC ($1.00M), Verition Fund Management LLC ($951.50K), and Avidity Partners Management LP ($926.90K).

Institutional investors have bought a total of 24,253,779 shares in the last 24 months. This purchase volume represents approximately $443.49M in transactions.

Of the 40 institutional investors that sold Zentalis Pharmaceuticals stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: FMR LLC ($4.68M), State Street Corp ($1.81M), Federated Hermes Inc. ($1.59M), Vanguard Group Inc. ($951.83K), Deutsche Bank AG ($387.15K), Sectoral Asset Management Inc. ($379.17K), and Capital International Investors ($308.09K).

Institutional investors have sold a total of 12,559,806 shares in the last 24 months. This volume of shares sold represents approximately $122.98M in transactions.